The Effect of Bcrp1 (Abcg2) on the <i>In vivo</i> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in PatientsPauline Breedveld, Jan H.M. Schellens, Dick Pluim et al.|Cancer Research|2005Cited by 351
Global Microbial IdentifierPeter R. Wielinga, Jørgen Schlundt, Saskia L. Smits et al.|Unknown|2017Cited by 28